Legend Biotech (LEGN) Total Debt (2021 - 2026)

Legend Biotech (LEGN) has 6 years of Total Debt data on file, last reported at $266.0 million in Q1 2026.

• Quarterly Total Debt fell 13.0% year-over-year to $266.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $266.0 million (down 13.0% YoY) and the FY2025 annual result came in at $638.2 million, up 111.89% from the prior year.
• Total Debt eased to $266.0 million in Q1 2026, from $638.2 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $638.2 million in Q4 2025 to a low of $253.4 million in Q1 2022.
• A 5-year average of $307.9 million and a median of $286.4 million in 2024 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2025 — Total Debt surged 111.89% — and 2026, when it retreated 13.0%.
• Tracing LEGN's Total Debt over 5 years: stood at $260.9 million in 2022, then rose by 7.82% to $281.3 million in 2023, then climbed by 7.06% to $301.2 million in 2024, then surged by 111.89% to $638.2 million in 2025, then plunged by 58.32% to $266.0 million in 2026.
• The last three Total Debt figures came in at $266.0 million (Q1 2026), $638.2 million (Q4 2025), and $314.8 million (Q3 2025), per Business Quant data.